Rongqing Pan

Rongqing Pan

Auto-generated profile, based on publicly available information

Rongqing Pan

Dana-Farber Cancer Institute, Boston, MA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
RPRongqing Pan
Rongqing Pan
LHLeah J. Hogdal
Leah J. Hogdal
JBJuliana M. Benito
Juliana M. Benito
DBDonna Bucci
Donna Bucci
LHLina Han
Lina Han
ALAnthony G. Letai
Anthony G. Letai
B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion. It remains a challenge to identify those tumors that are best treated by inhibition of BCL-2. Here, we demonstrate that acute myeloid leukemia (AML) cell lines, primary patient samples, and murine primary xenografts are very sensitive to treatment with the selective BCL-2 antagonist ABT-199. In primary patient cells, the median IC50 was approximately 10 nmol/L, and cell death occurred within 2 hours. Our ex vivo sensitivity results compare favorably with those observed for chronic lymphocytic leukemia, a disease for which ABT-199 has demonstrated consistent activity in clinical trials. Moreover, mitochondrial studies using BH3 profiling demonstrate activity at the mitochondrion that correlates well with cytotoxicity, supporting an on-target mitochondrial mechanism of action. Our protein and BH3 profiling studies provide promising tools that can be tested as predictive biomarkers in any clinical trial of ABT-199 in AML. Significance: Although targeting BCL-2 has largely been investigated in lymphoid cancers, we present preclinical results of targeting BCL-2 in AML. These results support clinical testing of the small-molecule BCL-2 antagonist ABT-199 in AML, accompanied by testing of predictive biomarkers used in this study. Cancer Discov; 4(3); 362–75. ©2013 AACR. See related commentary by Hockenbery, p. 278 This article is highlighted in the In This Issue feature, p. 259

1 December 2017 in Cancer Cell
Verified
Journal Article
Closed access
RPRongqing Pan
Rongqing Pan
VRVivian Ruvolo
Vivian Ruvolo
HMHong Mu
Hong Mu
JLJoel D. Leverson
Joel D. Leverson
GNGwen Nichols
Gwen Nichols
MAMichael Andreeff
Michael Andreeff

20 April 2022 in Cell
Verified
Journal Article
Closed access
RPRongqing Pan
Rongqing Pan
JRJeremy Ryan
Jeremy Ryan
DPDeng Pan
Deng Pan
KWKai W. Wucherpfennig
Kai W. Wucherpfennig
ALAnthony Letai
Anthony Letai

16 July 2015 in Blood
Verified
Journal Article
Closed access
PDF file
RPRongqing Pan
Rongqing Pan
VRVivian R. Ruvolo
Vivian R. Ruvolo
JWJun Wei
Jun Wei
MKMarina Konopleva
Marina Konopleva
JRJohn C. Reed
John C. Reed
PRPeter P. Ruvolo
Peter P. Ruvolo
Key Points: Mcl-1 inhibition by pan-active Bcl-2 inhibitor (–)BI97D6 kills AML cells via induction of mitochondrial apoptosis. Mcl-1 inhibition by (–)BI97D6 overcomes intrinsic and extrinsic drug resistance to ABT-737.

2 February 2011 in FEMS Yeast Research
Verified
Journal Article
Open access
PDF file
RPRongqing Pan
Rongqing Pan
JZJi Zhang
Ji Zhang
WSWei-Liang Shen
Wei-Liang Shen
ZTZheng-Qing Tao
Zheng-Qing Tao
SLShun-Peng Li
Shun-Peng Li
XYXin Yan
Xin Yan
A rapid and convenient method is presented for unmarked gene deletions in Pichia pastoris. Cre/mutated lox system, Zeocin® (Invitrogen) resistance ma

21 May 2014 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
PRPeter P. Ruvolo
Peter P. Ruvolo
VRVivian R. Ruvolo
Vivian R. Ruvolo
RJRodrigo Jacamo
Rodrigo Jacamo
JBJared K. Burks
Jared K. Burks
ZZZhihong Zeng
Zhihong Zeng
MAMichael Andreeff
Michael Andreeff